Fact Sheet for Healthcare Providers: Diazyme DZ-Lite SARS-CoV-2 IgM CLIA Kit | NLM

Disaster Information Management Research Center | NLM

Fact Sheet for Healthcare Providers: Diazyme DZ-Lite SARS-CoV-2 IgM CLIA Kit

08/17/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 8/17/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Diazyme DZ-Lite SARS-CoV-2 IgM CLIA Kit. The Diazyme DZ-Lite SARS-CoV-2 IgM CLIA Kit is authorized for the detection of antibodies to SARS-CoV-2 in human serum or plasma (potassium EDTA, disodium EDTA and lithium heparin). (PDF)